Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

294.93USD
11:59am EDT
Change (% chg)

$7.01 (+2.43%)
Prev Close
$287.92
Open
$291.16
Day's High
$295.56
Day's Low
$290.29
Volume
640,391
Avg. Vol
1,458,881
52-wk High
$329.83
52-wk Low
$244.28

Latest Key Developments (Source: Significant Developments)

Biogen appoints Anabella Villalobos senior vice president, Biotherapeutic & Medicinal Sciences
Monday, 31 Jul 2017 09:00am EDT 

July 31 (Reuters) - Biogen Inc :Biogen appoints Anabella Villalobos senior vice president, Biotherapeutic & Medicinal Sciences.  Full Article

Abarca Health signs reimbursement contract with Biogen for select products
Thursday, 27 Jul 2017 02:41pm EDT 

July 27 (Reuters) - Abarca Health::Signed value-based reimbursement contract with Biogen for select products in Biogen's leading multiple sclerosis portfolio​.  Full Article

Biogen says in July 2017 learned that prosecution office of Milan is investigating interactions with some healthcare providers in Italy - SEC Filing
Tuesday, 25 Jul 2017 06:37pm EDT 

July 25 (Reuters) - Biogen Inc :Biogen says in July 2017 learned that prosecution office of Milan is investigating interactions with some healthcare providers in Italy - SEC Filing.Biogen says cooperating with the government in investigation by prosecution office of Milan.  Full Article

Biogen CEO: "we will explore deals of all sizes"
Tuesday, 25 Jul 2017 09:57am EDT 

July 25 (Reuters) - Biogen Inc :Biogen CEO: "overall, we maintain our global market share in multiple sclerosis (treatments)".Biogen CEO: global Tecfidera Q2 revenues of $1.1 billion is a 13% increase versus the prior year; about half of that growth was driven by volume.Biogen CEO assumes continued strong Spinraza growth in U.S. patients, but expects growth to slow as patients move from loading dose to maintenance therapy.Biogen CEO: "we aim to...expand access to our products by shifting from transactional to value-based contracting".Biogen CEO: "we believe Spinraza will become one of our largest commercial assets, shifting the center of gravity for biogen beyond MS to generate new growth".Biogen exec: "there's a need for a leader in neuroscience. Our goal is to be that leader.".Biogen exec: "we believe the future growth we can generate from our neuroscience portfolio is not solely contingent on aducanumab".Biogen CEO: "we will explore deals of all sizes".Biogen exec says co does not comment on interim analyses, when asked about aducanumab.Biogen CEO: it appears that the epidemiology and prevalence (of SMA) might be slightly higher than anticipated. "This is what I hear from different geographies".  Full Article

Biogen reports Q2 EPS $4.07
Tuesday, 25 Jul 2017 06:30am EDT 

July 25 (Reuters) - Biogen Inc :Biogen reports record quarterly revenues of $3.1 billion, raises full year revenue guidance.Q2 revenue $3.1 billion versus I/B/E/S view $2.81 billion.Sees FY non-GAAP earnings per share $20.80 to $21.40.Sees FY GAAP earnings per share $17.05 to $17.65.Sees FY revenue about $11.5 billion to $11.8 billion.Qtrly Tecfidera revenue of $1,111 million versus $987 million in the same quarter last year.Sees 2017 revenue is expected to be approximately $11.5 to $11.8 billion.Says qtrly Avonex revenue of $557 million versus. $606 million in the same quarter last year.Q2 plegridy revenue of $133 million versus. $123 million in the same quarter last year.Q2 Tysabri revenue of $496 million versus. $497 million in the same quarter last year.Sees GAAP and non-GAAP SG&A expense is expected to be approximately 15 pct to 16 pct of total revenue in 2017.Sees 2017 GAAP diluted EPS is expected to be between $17.05 and $17.65.Sees 2017 non-GAAP diluted EPS is expected to be between $20.80 and $21.40.Full year guidance for GAAP diluted eps reflects impact of $120 million GAAP-only pre-tax charge recognized in Q2.FY2017 earnings per share view $20.38, revenue view $11.40 billion -- Thomson Reuters I/B/E/S.Says announced an updated strategic framework to drive long-term growth.Says through end of decade, Biogen expects cash flows to "significantly increase".  Full Article

Forward Pharma announces planned distribution of EUR 19.45 per share to shareholders
Tuesday, 18 Jul 2017 08:05am EDT 

July 18 (Reuters) - Forward Pharma A/S ::Forward Pharma announces planned distribution of EUR 19.45 per share to shareholders.Forward Pharma A/S - plans to return EUR 19.45 per share amounting to a total of EUR 917.7 million to its shareholders through a capital reduction.Forward Pharma A/S - plans to complete capital reduction in early September 2017.Forward Pharma - decision is based on careful evaluation of most appropriate capital allocation strategy after receipt of non-refundable $1.25 billion cash fee from Biogen.Forward Pharma - capital reduction aligns amount of working capital with adjusted business activities following settlement and license agreement with Biogen.Forward Pharma A/S - shareholders representing over two-thirds of voting share capital have irrevocably agreed to vote in favor of capital reduction.  Full Article

Ionis receives $10 mln milestone payment from Biogen
Monday, 17 Jul 2017 07:00am EDT 

July 17 (Reuters) - Ionis Pharmaceuticals Inc -:Ionis earns $10 million milestone payment from Biogen for advancing a new program in its neurology collaboration.Ionis Pharmaceuticals Inc- ‍earned a $10 million milestone payment from biogen associated with validation of an undisclosed neurological disease target​.  Full Article

Biogen Canada Inc: Spinraza gets notice of compliance from Health Canada
Tuesday, 4 Jul 2017 09:21am EDT 

July 4 (Reuters) - Biogen Inc :Biogen Canada Inc says Spinraza receives notice of compliance from Health Canada for treatment of 5Q spinal muscular atrophy.  Full Article

Biogen appoints Ginger Gregory as chief human resources officer
Tuesday, 20 Jun 2017 07:30am EDT 

June 20 (Reuters) - Biogen Inc ::Biogen appoints Ginger Gregory executive vice president, chief human resources officer.Biogen Inc - Gregory, was most recently chief human resources officer at Shire Pharmaceuticals.  Full Article

Alexion Pharmaceuticals names Paul Clancy as CFO
Tuesday, 13 Jun 2017 04:30pm EDT 

June 13 (Reuters) - Alexion Pharmaceuticals Inc :Alexion names Paul Clancy chief financial officer.Alexion Pharmaceuticals Inc - Clancy will succeed Dave Anderson, who will continue to serve as CFO until july 31, 2017.For past 16 years, Clancy has been employed by Biogen where he has served as CFO for last ten years.Alexion Pharmaceuticals Inc - Clancy most recently served as executive vice president, finance and CFO and a member of executive committee of Biogen.  Full Article

BRIEF-Paulson & Co takes share stake in Apple, dissolves share stake in Sarepta, Biogen

* Ups share stake in T-Mobile US Inc by 46.1 percent to 6.1 million shares - SEC filing